Results 101 to 110 of about 882 (153)

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +1 more source

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents

Frontiers in Microbiology
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury, Emily Salisbury, Kieran Mulroney, Kieran Mulroney, Malgorzata K. Kopczyk, Malgorzata K. Kopczyk, Teagan Paton, Teagan Paton, Christine F. Carson, Wai Shaun Ho, Wai Shaun Ho, Aron Chakera, Aron Chakera, Aron Chakera   +13 more
doaj   +1 more source

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections

Antimicrobial Agents and Chemotherapy
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam.
Sara M. Karaba, Dariusz A. Hareza, Jose M. Munita, Jose R. W. Martinez, Yehudit Bergman, Armani M. Hawes, Zackery P. Bulman, Sara E. Cosgrove, Patricia J. Simner, Pranita D. Tamma   +9 more
doaj   +1 more source

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties

Transplant International
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi, Andrea Lombardi, Davide Mangioni, Giulia Viero, Laura Alagna, Giulia Renisi, Paola Saltini, Alessandra Bandera, Alessandra Bandera   +8 more
doaj   +1 more source

Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae

International Journal of Pharmaceutical Sciences Review and Research, 2023
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire   +1 more source

Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: a valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections?

Objective: To assess whether attaining an aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target of therapeutic drug monitoring (TDM)-guided continuous infusion (CI) meropenem-vaborbactam monotherapy may be a valuable strategy for maximizing the
Giorgi, Beatrice, Secci, Benedetta, Gatti, Milo, Viale, Pierluigi, Bonazzetti, Cecilia, Tonetti, Tommaso, Cojutti, Pier Giorgio, Siniscalchi, Antonio, Pea, Federico, Ambretti, Simone, Rinaldi, Matteo   +10 more
core   +1 more source

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections [PDF]

Infectious Diseases and Therapy, 2021
openaire   +2 more sources

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections

Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M, Mazzei, P, Bokesch, PM, Bradley, JS, Capriati, A, Fornari, C, Habboubi, N, Auriol, FK, Borella, E, Vallespir, BP, Magalhaes, P, Hoover, R, Piana, C, Arrieta, A, Pasqua, OD   +14 more
core  

Biochemical Activity of Vaborbactam [PDF]

Antimicrobial Agents and Chemotherapy, 2020
The most common mechanism of resistance to β-lactams antibiotics in Gram-negative bacteria is production of β-lactamase enzymes capable of cleaving the β-lactam ring. Inhibition of β-lactamase activity with small-molecule drugs is a proven strategy to restore the potency of many β-lactam antibiotics.
Olga Lomovskaya, Ruslan Tsivkovski
exaly   +3 more sources